TP53 p.Arg282Trp
c.844C>T · rs28934574 · VCV12364
Computational evidence
| Protein change | ||
| AlphaMissense | 0.9462 | likely pathogenic ✓ concordant with ClinVar |
|---|---|---|
| REVEL | 0.896 | moderately pathogenic-leaning |
| SaProt | LLR -14.47 | damaging |
| ⇒ AlphaMissense, REVEL and SaProt all call this damaging. | ||
| Splicing | ||
| SpliceAI | — | not assessed · no allele here is in the release |
| Constraint at this position | ||
| Conservation | phyloP 6.5 | GERP -1.2, phastCons 1 |
| Regional constraint | o/e 0.89 | unconstrained · MANE · 6,982 bp · p 0.0085 · regional, not allelic |
| Overall | ||
| CADD | 28.0 | PHRED · no single calibrated threshold — expert panels disagree |
AlphaMissense carries the ACMG weight for missense; REVEL and SaProt are independent agreement signals.
Population frequency
Rarity supports pathogenicity (ACMG PM2); frequency above a disease-specific BA1/BS1 threshold argues against it. A variant frequent in one ancestry group can be near-absent in others, so a single global figure can mislead.
Cancer therapy — CIViC
| Disease | Therapies | Level | Significance |
|---|---|---|---|
| D | Dominant Negative | ||
| D | Neomorphic |
Variant & gene context
- Gene
- TP53
- Protein
- p.Arg282Trp
- Coding
- c.844C>T
- MANE Select
- NM_000546
- dbSNP
- rs28934574
- Type
- single nucleotide variant
- Location
- chr17:7673776 (GRCh38)
- Gene constraint
- LOEUF 0.449 · pLI 1.00 · ClinGen HI 3/3 (gnomAD)
- Structure
- AlphaFold pLDDT 75.83 · 321 PDB
- Residue 282
- a DNA-binding region; the 'interaction with axin1' region; a UniProt-annotated variant site (in sporadic cancers; somatic mutation); the 'interaction with e4f1' region; a UniProt-annotated variant site (in lfs; germline mutation and in sporadic cancers; somatic mutation); a UniProt-annotated variant site (in a sporadic cancer; somatic mutation); a UniProt-annotated variant site (in a familial cancer not matching lfs; germline mutation and in sporadic cancers; somatic mutation); a UniProt-annotated variant site (in lfs; germline mutation and in sporadic cancers; somatic mutation; does not induce snai1 degradation); the 'disordered' region; an α-helix; the 'interaction with ccar2' region; the 'interaction with hipk1' region; the 'required for interaction with znf385a' region
Disease context
diffuse pediatric-type high-grade glioma, H3-wildtype and IDH-wildtype — disease report on Sugi Atlas → Associated genes, phenotypes, clinical trials & treatmentsAlso linked: colorectal canceradrenocortical carcinoma, hereditaryhead and neck squamous cell carcinomahereditary neoplastic syndromeanaplastic astrocytomapleomorphic xanthoastrocytomaLi-Fraumeni syndromeovarian neoplasmLi-fraumeni-like syndrome
Similar variants
- TP53 p.Arg282Leu Uncertain significance ★★★ ⚠ same residue
- TP53 p.Arg282Gly Pathogenic ★★ same residue
- TP53 p.Arg282Pro Pathogenic/Likely pathogenic ★★ same residue
- TP53 p.Arg282= Likely benign ★★ same residue
- TP53 p.Arg282Gln Conflicting classifications of pathogenicity ★ ⚠ same residue
- TP53 p.Arg282fs Pathogenic ★★ same residue
- TP53 p.Arg282_Arg283insThr Uncertain significance ★ same residue
- TP53 p.Arg282_His296del Likely pathogenic same residue
Built on 18 open, versioned datasets — ClinVar, gnomAD, AlphaMissense, REVEL, ClinGen & more — plus Sugi Variant's own cross-source analysis. Source data 2026-01–2026-10, ClinVar 2026-10. Full sources & versions →
Cite Sugi Variant
Gür T. Sugi Variant: A Deterministic Per-Variant Germline Reference from a Knowledge Graph for Humans and AI Agents. 2026. doi:10.5281/zenodo.21509445. This variant: https://sugi.bio/variant/tp53-p-arg282trp (accessed [today's date]).
Preprint & method: sugi.bio/variant/method Machine-readable: this page as Markdown